We give you a written timeline estimate for your case before you commit.Ask about Carvykti
Is Carvykti available in Saudi Arabia? Status, route and cost
A plain answer for families in Saudi Arabia, checked against FDA, regulator and manufacturer sources on 17 October 2026.
Reviewed by the Reserve Meds clinical operations team on 17 October 2026.
Is Carvykti available in Saudi Arabia?
Yes. Carvykti is registered in Saudi Arabia and listed in SFDA's public Drugs List (checked 17 October 2026). It is a one-time CAR-T cell therapy for relapsed or refractory multiple myeloma, given only at qualified centers. Your specialist refers the patient, and the center confirms eligibility and funding. No import request is normally needed.
- Registration: Registered in Saudi Arabia: it is listed in the SFDA public Drugs List (entry 0908233977), checked 17 October 2026.
- Access route: Referral to a qualified treatment center in Saudi Arabia (registered, so no import request is normally needed).
- Who acts: your treating specialist refers the patient; the treatment center accepts the patient and confirms funding.
- Timeline: We give you a written timeline estimate for your case before you commit.
- Medicine price: quote on request. Every case gets a written custom quote before you commit.
Status in Saudi Arabia, with dates
- Carvykti is listed in the SFDA public Drugs List (entry 0908233977), checked 17 October 2026. (source)
What Carvykti is
Carvykti (ciltacabtagene autoleucel) is made by Janssen (Johnson & Johnson) with Legend Biotech. The US FDA first approved Carvykti on 28 February 2022. Since 5 April 2024 it is approved for adults with relapsed or refractory multiple myeloma after at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, whose disease is refractory to lenalidomide.
How it is given: The patient's own T cells are collected, modified in a lab, and given back as a one-time infusion at a certified treatment center, with close monitoring afterwards. It has boxed warnings for cytokine release syndrome, neurologic side effects, parkinsonism and Guillain-Barre syndrome, HLH/MAS, prolonged low blood counts and secondary blood cancers. In the US it is given only through a restricted safety program (REMS).
How access works in Saudi Arabia
Because Carvykti is registered, the usual route is through a qualified treatment center in Saudi Arabia. Your specialist sends a referral with the medical records, the center checks eligibility, and the family confirms funding with the center, an insurer or a government program.
If no local center can treat the patient, for example because of eligibility, center capacity or an age outside the local label, your specialist can refer the patient to a qualified center abroad. A named-patient import is meant for medicines that are not registered, so it is not the usual route here.
Public lists can lag behind decisions, so the treating center or hospital pharmacy confirms the current status before treatment is planned.
Who does what
- Your treating specialist decides whether Carvykti is right for the patient and writes the referral or prescription.
- The hospital or treatment center checks eligibility, plans treatment and is responsible for giving it safely.
- The Saudi Food and Drug Authority (SFDA) registers medicines and decides on any import request for a medicine that is not registered.
- Janssen (Johnson & Johnson) with Legend Biotech makes Carvykti and decides where it can be supplied.
- Reserve Meds helps your family understand the steps, organizes records and communication, and, where an import is needed, arranges US supply through our licensed wholesale partner. We do not give medical advice.
Documents you will usually need
- The myeloma treatment history (prior lines, lenalidomide-refractory status) and recent staging and blood tests
- A referral letter from the treating specialist with the diagnosis, past treatments and why this treatment is being considered
- Recent clinic notes, imaging and laboratory results
- Identity documents and a funding plan (personal funds, insurer approval or a government treatment decision)
- Passport and travel documents, if treatment happens abroad
Steps
- Referral. Your specialist prepares a referral letter and the medical records.
- Center review. A qualified treatment center reviews the records and decides whether the patient is eligible.
- Funding. The family confirms funding with the center, an insurer or a government program.
- Preparation. The center runs tests and, for cell-based products, collects cells to make the treatment.
- Treatment and follow-up. The patient is treated and then followed up by the center and the home specialist.
Timeline and cost
We give you a written timeline estimate for your case before you commit. The treating center, the regulator and the manufacturer set their own timelines.
Medicine price: quote on request. Your total cost depends on the dose, travel or shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.
How Reserve Meds helps
Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We coordinate access to FDA-approved medicines only. We help your family understand the route, organize records and communication with the hospital or center, and, where an import is approved, arrange US supply and shipping. We do not prescribe, and we do not decide what the regulator or a treatment center approves.
Ask about Carvykti in Saudi Arabia
Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.
Frequently asked questions
Is Carvykti registered in Saudi Arabia?
Yes. Carvykti is registered in Saudi Arabia and listed in SFDA's public Drugs List (checked 17 October 2026). Public lists can lag behind registration decisions, so the hospital pharmacy confirms the status in SFDA's system before anything is filed.
How do patients in Saudi Arabia get Carvykti?
It is a one-time CAR-T cell therapy for relapsed or refractory multiple myeloma, given only at qualified centers. Your specialist refers the patient, and the center confirms eligibility and funding. No import request is normally needed.
How long does it take to get Carvykti in Saudi Arabia?
We give you a written timeline estimate for your case before you commit. The treating center, the regulator and the manufacturer set their own timelines, and we tell you honestly what depends on them.
How much does Carvykti cost?
Medicine price: quote on request. Your total cost, including any travel, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.
Can Carvykti be given in Saudi Arabia instead of abroad?
Yes, if a qualified center in Saudi Arabia accepts the patient. Ask your specialist which centers offer it today.
Sources
Checked on 17 October 2026. Regulator rules and lists change. Your hospital pharmacy or treatment center confirms the current position before anything is filed.